CAJ | 학술논문

目的：观察阿托伐他汀钙治疗急性脑梗死的临床疗效及对血清白细胞介素-6(IL-6)水平的影响。方法将三台县人民医院100例发病72 h 内收治的急性脑梗死患者随机分为治疗组和对照组各50例。两组均给予常规治疗，治疗组在此基础上加用阿托伐他汀钙10 mg/d 口服，连用14 d。于治疗前、治疗后14 d 检测两组患者血清 IL-6水平，并比较两组神经功能缺损评分。结果两组治疗14 d 后神经功能缺损评分较治疗前明显改善，且治疗组改善程度较对照组更明显，差异有统计学意义(P <0.05)。治疗组治疗后血清 IL-6水平较治疗前明显降低(P <0.05)，且低于对照组，差异有统计学意义(P <0.05)。对照组治疗后血清 IL-6降低不明显(P >0.05)。结论阿托伐他汀钙能降低急性脑梗死患者的 IL-6水平，从而改善其神经功能。
목적：관찰아탁벌타정개치료급성뇌경사적림상료효급대혈청백세포개소-6(IL-6)수평적영향。방법장삼태현인민의원100례발병72 h 내수치적급성뇌경사환자수궤분위치료조화대조조각50례。량조균급여상규치료，치료조재차기출상가용아탁벌타정개10 mg/d 구복，련용14 d。우치료전、치료후14 d 검측량조환자혈청 IL-6수평，병비교량조신경공능결손평분。결과량조치료14 d 후신경공능결손평분교치료전명현개선，차치료조개선정도교대조조경명현，차이유통계학의의(P <0.05)。치료조치료후혈청 IL-6수평교치료전명현강저(P <0.05)，차저우대조조，차이유통계학의의(P <0.05)。대조조치료후혈청 IL-6강저불명현(P >0.05)。결론아탁벌타정개능강저급성뇌경사환자적 IL-6수평，종이개선기신경공능。
Objective To observe the clinical effects of atorvastatin calcium in the treatment of patients with acute cerebral infarction and its influence on serum interleukin 6 (IL-6).Methods A total of 100 patients within 72h of the onset of acute cerebral infarction were randomly divided into treatment group(n=50)and control group (n=50).Both groups were given conventional treatment,and the treatment group were given additional atorvastatin calcium 10 mg/d orally for 14 days.Changes of serum IL-6 levels of the two groups before and after treatment were tested and neurological deficit scores were compared between the two groups.Results After 14 days of treatment, the neurological deficit scores were obviously improved in both groups,and the improvement in treatment group were more apparent than control group.The difference was statistically significant (P <0.05).After treatment,the serum IL-6 levels of treatment group were significantly lower than those before treatment (P < 0.05 ),and were lower than those of control group,the difference of which was statistically significant(P < 0.05 ).There was no apparent decrease in the serum IL-6 levels in control group (P > 0.05 ).Conclusion Atorvastatin calcium can improve the neurological function of patients with acute cerebral infarction through reducing the serum IL-6 levels.